Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-994 in acute sleep phase delay
NCT04551079Phase 1Completed
- Sponsor
- Takeda
- Start
- Sep 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of firazorexton in narcolepsy (3 arms), sponsored by Takeda. Primary endpoints: Number of Participants who Experience at Least 1 Treatment Emergent Adverse Event, Number of Participants who Meet the Markedly Abnormal Value for Safety Laboratory Tests and 3 more. Started Sep 2020; status: completed.
02
Drugs
firazorexton
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NCT04551079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04551079.